EBV T-cell therapy for certain virus-related lymphomas
Part of Infections clinical trials.
This early-phase trial tests lab-made “memory” immune T cells that target Epstein-Barr virus (EBV). It may help people whose EBV infection has caused lymphomas or serious complications after a transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an EBV-related lymphoma or EBV complications (or high-risk immune conditions) and may be planned for an allogeneic transplant
- Or you have EBV-driven PTLD that happened after a transplant of the body (HCT) or an organ (SOT)
- If you can become pregnant, you must have a negative pregnancy test before treatment
- You (and a parent/guardian if needed) must be able to sign informed consent
- You are not currently receiving anti-thymocyte globulin or Campath within 28 days of the planned infusion
- You do not have active severe graft-versus-host disease (grades III–IV)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an immune therapy made from EBV-targeted T-cells to treat EBV infections that do not improve with standard anti-viral medicines. It may help by strengthening the body’s ability to fight EBV after certain transplants or immune problems.
This trial tests whether special immune cells (called EBV-TCR-T cells) can help clear the Epstein-Barr virus in people who still have high virus levels after a stem cell transplant. It's an experimental therapy for those whose virus hasn't responded to standard care.
This trial tests a new treatment using specially trained immune cells (TCR-T cells) to fight Epstein-Barr virus (EBV) infections that can occur after a stem cell transplant for blood cancer. It may help control the virus and prevent complications.
This early-phase study tests a lab-made immune cell treatment (cytotoxic T-lymphocytes) for certain lymphomas and related diseases that test positive for the Epstein-Barr virus (EBV). It may help your immune system attack EBV-infected cancer cells, especially after the cancer has come back or when transplant isn’t suitable.
This trial tests a new immune cell therapy (EBV-TCR-T cells) for people with a severe immune reaction caused by the Epstein-Barr virus (EBV-HLH) or active EBV infection. The treatment uses special cells from a matched donor to help your body fight the virus.
This trial tests a new cell therapy (TCR-T cells) for people with EBV-positive lymphoma that has not responded to standard treatments or has come back. The therapy uses your own immune cells that have been specially trained to find and attack cancer cells carrying the EBV virus.
Hear when a new EBV Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.